| 49.52 -0.47 (-0.94%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 59.62 | 1-year : | 69.64 |
| Resists | First : | 51.04 | Second : | 59.62 |
| Pivot price | 49.46 |
|||
| Supports | First : | 47.07 | Second : | 44.61 |
| MAs | MA(5) : | 49.9 |
MA(20) : | 49.01  |
| MA(100) : | 48.61 |
MA(250) : | 50.67 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 58.4 |
D(3) : | 67.4 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 60.11 | Low : | 44.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SNY ] has closed below upper band by 48.2%. Bollinger Bands are 36.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 50.47 - 50.72 | 50.72 - 50.96 |
| Low: | 48.72 - 49.03 | 49.03 - 49.34 |
| Close: | 48.95 - 49.44 | 49.44 - 49.92 |
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Fri, 24 Oct 2025
Sanofi Faces EU Setback for Rezurock Amidst Positive Developments - TipRanks
Fri, 24 Oct 2025
Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com
Fri, 24 Oct 2025
Sanofi (SNY) Boosts Q3 Profits Through Strategic Pharma Launches - GuruFocus
Fri, 24 Oct 2025
Sanofi Q3 Profit Edges Down, Net Sales Rise; Confirms FY25 View, Sees Profitable Growth In FY26 - Nasdaq
Thu, 23 Oct 2025
Sanofi (SNY) Poised to Benefit from Ventyx's Breakthrough Data - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,440 (M) |
| Shares Float | 1,100 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 4,110 (K) |
| Shares Short P.Month | 5,030 (K) |
| EPS | 3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 57.52 |
| Profit Margin | 19.9 % |
| Operating Margin | 18 % |
| Return on Assets (ttm) | 4.6 % |
| Return on Equity (ttm) | 9 % |
| Qtrly Rev. Growth | -5.7 % |
| Gross Profit (p.s.) | 13.36 |
| Sales Per Share | 18.74 |
| EBITDA (p.s.) | 4.95 |
| Qtrly Earnings Growth | 266.6 % |
| Operating Cash Flow | 11,210 (M) |
| Levered Free Cash Flow | 8,780 (M) |
| PE Ratio | 16.5 |
| PEG Ratio | 0 |
| Price to Book value | 0.86 |
| Price to Sales | 2.64 |
| Price to Cash Flow | 10.77 |
| Dividend | 2.21 |
| Forward Dividend | 0 |
| Dividend Yield | 4.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|